PMLive12d
AstraZeneca/Ionis’ Wainzua granted EC approval to treat rare disease ATTRv-PN
AstraZeneca (AZ) and Ionis Pharmaceuticals’ Wainzua (eplontersen) has been approved by the European Commission (EC) to treat ...
Business Insider17d
Ionis and AstraZeneca’s WAINZUA gets EU approval for ATTRv-PN treatment
WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector. The approval by the European Commission EC follows the ...
Hosted on MSN16d
AstraZeneca and Ionis win EU approval for ATTR polyneuropathy
The drug has been approved to treat hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (ATTRv-PN). This marks the second major regulatory ...
Business Wire17d
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector. The approval by the European Commission (EC) follows the ...
Zacks.com on MSN15d
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
The EC and CHMP decisions are based on positive data from the phase III NEURO-TTRansform study, which evaluated the safety ...
Nasdaq16d
Ionis Pharma Reports Approval Of WAINZUA In The EU - Quick Facts
WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN. WAINZUA was approved under the brand name WAINUA for the treatment of ATTRv-PN in the U.S. in December 2023 and has ...